BioSig Technologies (NASDAQ:BSGM) Shares Down 8.4%

Shares of BioSig Technologies, Inc. (NASDAQ:BSGM) dropped 8.4% during mid-day trading on Friday . The company traded as low as $1.35 and last traded at $1.41. Approximately 199,537 shares were traded during trading, a decline of 80% from the average daily volume of 983,634 shares. The stock had previously closed at $1.54.

BioSig Technologies Price Performance

The stock has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $2.63. The stock has a market cap of $15.79 million, a PE ratio of -0.29 and a beta of 1.21.

Institutional Investors Weigh In On BioSig Technologies

Institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new position in shares of BioSig Technologies during the fourth quarter worth about $2,660,000. Vanguard Group Inc. lifted its stake in shares of BioSig Technologies by 44.1% during the third quarter. Vanguard Group Inc. now owns 2,383,866 shares of the company’s stock worth $1,166,000 after purchasing an additional 729,856 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of BioSig Technologies by 67.0% during the second quarter. Geode Capital Management LLC now owns 565,738 shares of the company’s stock worth $707,000 after purchasing an additional 227,054 shares in the last quarter. Advisor Resource Council lifted its stake in shares of BioSig Technologies by 19.6% during the third quarter. Advisor Resource Council now owns 1,077,906 shares of the company’s stock worth $527,000 after purchasing an additional 176,700 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in shares of BioSig Technologies by 32.1% during the second quarter. BlackRock Inc. now owns 594,162 shares of the company’s stock worth $743,000 after purchasing an additional 144,300 shares in the last quarter. Hedge funds and other institutional investors own 7.16% of the company’s stock.

BioSig Technologies Company Profile

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.